Results 31 to 40 of about 2,247 (204)

Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system

, 2021
Background To investigate the adverse event (AE) profile of tedizolid and linezolid in post-marketing surveillance. Research design and methods We queried the worldwide FDA Adverse Event Reporting System and selected all records where tedizolid and ...
Fusaroli M., De Ponti F., Gatti M., Moretti U., Poluzzi E., Raschi E.   +5 more
core   +2 more sources

Effect of the human endotoxin challenge on tedizolid tissue penetration

, 2022
The effects of the human endotoxin challenge on tissue pharmacokinetics are unknown. In the present study, we aimed to assess the effect of the endotoxin challenge on interstitial fluid pharmacokinetics of tedizolid in healthy volunteers using ...
Matzneller, Peter, Jilma, Bernd, Lackner, Edith, Michael Wölfl‐Duchek, Al Jalali, Valentin, Zeitlinger, Markus, Schörgenhofer, Christian, Bauer, Martin, Dorn, Christoph, Valentin al Jalali, Peter Matzneller, Christian Schoergenhofer, Edith Lackner, Martin Bauer, Markus Zeitlinger, Beatrix Wulkersdorfer, Wölfl-Duchek, Michael, Wulkersdorfer, Beatrix, Anselm Jorda, Schoergenhofer, Christian, Jorda, Anselm, Jalali, Valentin A. L., Christoph Dorn, Wölfl‐Duchek, Michael, Bernd Jilma   +24 more
core   +1 more source

In vitro activity of tedizolid against the Mycobacterium abscessus complex [PDF]

, 2018
International audienceInfections due to Mycobacterium abscessus carry a poor prognosis since this rapidly growing mycobacterium is intrinsically resistant to most antibiotics.
Michel Arthur, Vincent Dubée, Daria Soroka, Heym, Beate, Herrmann, Jean-Louis, J.L. Gaillard, Delphine Dorchène, Compain, Fabrice, Arthur, Michel, Beate Heym, Jean-Louis Gaillard, Dorchène, Delphine, Fabrice Compain, Dubée, Vincent, V. Dubée, J.L. Herrmann, D. Dorchène, Gaillard, Jean-Louis, F. Compain, B. Heym, D. Soroka, M. Arthur, Soroka, Daria, Jean-Louis Herrmann   +23 more
core   +1 more source

In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus Associated with Skin and Soft Tissue Infections

Antibiotics, 2023
Skin and soft tissue infections (SSTIs) are associated with significant morbidity and healthcare costs, especially when caused by methicillin-resistant Staphylococcus aureus (MRSA).
Sofia Maraki, Viktoria Eirini Mavromanolaki, Dimitra Stafylaki, Evangelia Iliaki-Giannakoudaki, George Hamilos   +4 more
doaj   +1 more source

Optimizing Tedizolid Dosing in Cerebral Nocardiosis: Clinical Impact of Direct Unbound Concentration Measurement and Population PK Modelling in Two Cases. [PDF]

JAC Antimicrob Resist
International audienceIntroduction: Tedizolid, a second-generation oxazolidinone, exhibits potent in vitro activity against Gram-positive bacteria, including Nocardia species, and has a more favourable safety profile than linezolid during prolonged use ...
Marc-Olivier V, Margaux B, David L, Anne Christine J, Heidi W, Christophe A, Laure A, Alexia C.   +7 more
europepmc   +2 more sources

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis

Frontiers in Pharmacology, 2021
Background:Mycobacteriumtuberculosis [Mtb] could be present in different metabolic population in the lung lesions, and nonreplicating persisters [NRP], associated with latent tuberculosis [TB], are the most difficult to kill.Objective: Test the ...
Shashikant Srivastava, Shashikant Srivastava, Shashikant Srivastava, Kayle N. Cirrincione, Devyani Deshpande, Tawanda Gumbo, Tawanda Gumbo, Tawanda Gumbo   +7 more
doaj   +1 more source

Synthesis, mechanism of action, and structure-activity relationships of 1,3-oxazolidinones as anti-bacterial Agent: A review [PDF]

المجلة العراقية للصيدلة, 2022
Background: 1,3-oxazolidinones are an important class of antibiotics that are recognized with higher activities against Gram-positive bacteria. linezolid, tedizolid phosphate, and radezolid are important examples of this group.
Ali Hantosh, Nawal Rajab, Faris Abachi
doaj   +1 more source

In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source

International Journal of Infectious Diseases, 2019
Objective: We tested the in vitro susceptibility to Tedizolid and Dalbavancin of Methicillin-resistant Staphylococcus aureus strains recovered from blood and wound cultures, and compared our results with studies conducted in the last four years.
Maya Azrad, Motti Baum, Assaf Rokney, Yish Levi, Avi Peretz   +4 more
doaj   +1 more source

Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease? [PDF]

, 2019
Background: Pulmonary infections caused by non-tuberculous mycobacteria (NTM) are hard to treat and have low cure rates despite intensive multidrug therapy.
Koeken, Valerie ACM, Hoefsloot, Wouter, Pennings, L.J., Pennings, Lian J, Pennings, Lian J., van Ingen, Jakko, Svensson, E.M., Svensson, Elin, Koeken, Valerie A. C. M., Hoefsloot, W., Wertheim, Heiman FL, Ruth, M.M., Ingen, J. van, Koeken, V.A.C.M., Svensson, Elin M, Ruth, Mike Marvin, Wertheim, Heiman F. L., Wertheim, H.F.L.   +17 more
core   +2 more sources

New and old oxazolidinones: tedizolid vs. linezolid [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2017
Tedizolid is a novel oxazolidinone that has been recently approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive pathogens, including MRSA.
Dekhnich A.V., Hachatryan N.N.
doaj